Convergence of neuro-endocrine-immune pathways in the pathophysiology of irritable bowel syndrome

World Journal of Gastroenterology

Volumn , Issue 27, 2014, Pages 8846-8858

  Buckley, Maria M ^a   O'Mahony, Siobhain M ^b   O'Malley, Dervla ^a,b  

^a UNIVERSITY COLLEGE CORK   (Ireland)

^b UNIVERSITY COLLEGE CORK   (Ireland)

Author keywords

Corticotropin releasing factor; Enteric nervous system; Proinflammatory cytokines; Stress; Vagus

Indexed keywords

CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; GLUCAGON LIKE PEPTIDE 1; GLUCOCORTICOID; HYDROCORTISONE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MONOCYTE CHEMOTACTIC PROTEIN 1; MOTILIN; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ABDOMINAL PAIN; ANXIETY; BLOATING; CINGULATE GYRUS; CONSTIPATION; DEPRESSION; DIARRHEA; DIET; DISEASE EXACERBATION; DYSBIOSIS; EMOTION; GASTROINTESTINAL INFECTION; GRAY MATTER; HUMAN; HYPERALGESIA; HYPERSENSITIVITY; IMMUNE SYSTEM; IRRITABLE COLON; MAST CELL; MICROFLORA; NEUROENDOCRINE SYSTEM; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SENSORY CORTEX; STRESS; T LYMPHOCYTE; VAGUS NERVE STIMULATION; ANIMAL; IMMUNOLOGY; INNERVATION; INTESTINE; IRRITABLE BOWEL SYNDROME; METABOLISM; NERVE TRACT; NEUROSECRETION; PROGNOSIS; RISK FACTOR; SIGNAL TRANSDUCTION;

ANIMALS; HUMANS; IMMUNE SYSTEM; INTESTINES; IRRITABLE BOWEL SYNDROME; NEURAL PATHWAYS; NEUROSECRETORY SYSTEMS; PROGNOSIS; RISK FACTORS; SIGNAL TRANSDUCTION;

EID: 84905393385     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i27.8846     Document Type: Review

References (176)

1. Drossman DA, Camilleri M, Mayer EA, Whitehead WE. AGA technical review on irritable bowel syndrome. Gastroenterology 2002; 123 : 2108-2131 [PMID: 12454866 DOI: 10.1053/gast.2002.37095]
2. Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F, Spiller RC. Functional bowel disorders. Gastroenterology 2006; 130: 1480-1491 [PMID: 16678561]
3. Thompson WG, Heaton KW, Smyth GT, Smyth C. Irritable bowel syndrome in general practice: prevalence, characteristics, and referral. Gut 2000; 46: 78-82 [PMID: 10601059]
4. El-Serag HB, Olden K, Bjorkman D. Health-related quality of life among persons with irritable bowel syndrome: a systematic review. Aliment Pharmacol Ther 2002; 16: 1171-1185 [PMID: 12030961]
5. Su AM, Shih W, Presson AP, Chang L. Characterization of symptoms in irritable bowel syndrome with mixed bowel habit pattern. Neurogastroenterol Motil 2014; 26: 36-45 [PMID: 23991913 DOI: 10.1111/nmo.12220]
6. Andrews EB, Eaton SC, Hollis KA, Hopkins JS, Ameen V, Hamm LR, Cook SF, Tennis P, Mangel AW. Prevalence and demographics of irritable bowel syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005; 22 : 935-942 [PMID: 16268967]
7. Saito YA, Schoenfeld P, Locke GR. The epidemiology of irritable bowel syndrome in North America: a systematic review. Am J Gastroenterol 2002; 97: 1910-1915 [PMID: 12190153 DOI: 10.1111/j.1572-0241.2002.05913.x]
8. Collins SM, Bercik P. The relationship between intestinal microbiota and the central nervous system in normal gastrointestinal function and disease. Gastroenterology 2009; 136: 2003-2014 [PMID: 19457424 DOI: 10.1053/j.gastro.2009.01.075]
9. Drossman DA, Chang L, Bellamy N, Gallo-Torres HE, Lembo A, Mearin F, Norton NJ, Whorwell P. Severity in irritable bowel syndrome: a Rome Foundation Working Team report. Am J Gastroenterol 2011; 106 : 1749-1759; quiz 1760 [PMID: 21747417 DOI: 10.1038/ajg.2011.201]
10. Stasi C, Rosselli M, Bellini M, Laffi G, Milani S. Altered neuro-endocrine-immune pathways in the irritable bowel syndrome: the top-down and the bottom-up model. J Gastroenterol 2012; 47: 1177-1185 [PMID: 22766747 DOI: 10.1007/s00535-012-0627-7]
11. Aggarwal A, Cutts TF, Abell TL, Cardoso S, Familoni B, Bremer J, Karas J. Predominant symptoms in irritable bowel syndrome correlate with specific autonomic nervous system abnormalities. Gastroenterology 1994; 106 : 945-950 [PMID: 8143999]
12. Mayer EA, Tillisch K, Bradesi S. Review article: modulation of the brain-gut axis as a therapeutic approach in gastrointestinal disease. Aliment Pharmacol Ther 2006; 24: 919-933 [PMID: 16948804]
13. Fukudo S . Stress and visceral pain: focusing on irritable bowel syndrome. Pain 2013; 154 Suppl 1: S63-S70 [PMID: 24021863]
14. Saper CB. The central autonomic nervous system: conscious visceral perception and autonomic pattern generation. Annu Rev Neurosci 2002; 25: 433-469 [PMID: 12052916 DOI: 10.1146/annurev.neuro.25.032502.111311]
15. Fukudo S, Kanazawa M. Gene, environment, and brain-gut interactions in irritable bowel syndrome. J Gastroenterol Hepatol 2011; 26 Suppl 3: 110-115 [PMID: 21443722 DOI: 10.1111/j.1440-1746.2011.06631.x]
16. Gillanders S, Wild M, Deighan C, Gillanders D. Emotion regulation, affect, psychosocial functioning, and well-being in hemodialysis patients. Am J Kidney Dis 2008; 51: 651-662 [PMID: 18371541 DOI: 10.1053/j.ajkd.2007.12.023]
17. Spaziani R, Bayati A, Redmond K, Bajaj H, Mazzadi S, Bienenstock J, Collins SM, Kamath MV. Vagal dysfunction in irritable bowel syndrome assessed by rectal distension and baroreceptor sensitivity. Neurogastroenterol Motil 2008; 20: 336-342 [PMID: 18179607 DOI: 10.1111/j.1365-2982.2007.01042.x]
18. Spetalen S, Sandvik L, Blomhoff S, Jacobsen MB. Autonomic function at rest and in response to emotional and rectal stimuli in women with irritable bowel syndrome. Dig Dis Sci 2008; 53: 1652-1659 [PMID: 17990112 DOI: 10.1007/s10620-007-0066-0]
19. van Orshoven NP, Andriesse GI, van Schelven LJ, Smout AJ, Akkermans LM, Oey PL. Subtle involvement of the parasympathetic nervous system in patients with irritable bowel syndrome. Clin Auton Res 2006; 16 : 33-39 [PMID: 16477493 DOI: 10.1007/s10286-006-0307-x]
20. Adeyemi EO, Desai KD, Towsey M, Ghista D. Characterization of autonomic dysfunction in patients with irritable bowel syndrome by means of heart rate variability studies. Am J Gastroenterol 1999; 94: 816-823 [PMID: 10086672 DOI: 10.1111/j.1572-0241.1999.00861.x]
21. Lomax AE, Sharkey KA, Furness JB. The participation of the sympathetic innervation of the gastrointestinal tract in disease states. Neurogastroenterol Motil 2010; 22: 7-18 [PMID: 19686308 DOI: 10.1111/j.1365-2982.2009.01381.x]
22. Pellissier S, Dantzer C, Canini F, Mathieu N, Bonaz B. Psychological adjustment and autonomic disturbances in inflammatory bowel diseases and irritable bowel syndrome. Psychoneuroendocrinology 2010; 35: 653-662 [PMID: 19910123 DOI: 10.1016/j.psyneuen.2009.10.004]
23. Cain KC, Jarrett ME, Burr RL, Hertig VL, Heitkemper MM. Heart rate variability is related to pain severity and predominant bowel pattern in women with irritable bowel syndrome. Neurogastroenterol Motil 2007; 19: 110-118 [PMID: 17244165]
24. Heitkemper M, Jarrett M, Cain KC, Burr R, Levy RL, Feld A, Hertig V. Autonomic nervous system function in women with irritable bowel syndrome. Dig Dis Sci 2001; 46: 1276-1284 [PMID: 11414305]
25. Jarrett ME, Burr RL, Cain KC, Hertig V, Weisman P, Heitkemper MM. Anxiety and depression are related to autonomic nervous system function in women with irritable bowel syndrome. Dig Dis Sci 2003; 48 : 386-394 [PMID: 12643620]
26. Ritchie J. Pain from distension of the pelvic colon by inflating a balloon in the irritable colon syndrome. Gut 1973; 14: 125-132 [PMID: 4696535]
27. Mayer EA, Tillisch K. The brain-gut axis in abdominal pain syndromes. Annu Rev Med 2011; 62 : 381-396 [PMID: 21090962 DOI: 10.1146/annurev-med-012309-103958]
28. Whitehead WE, Engel BT, Schuster MM. Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci 1980; 25: 404-413 [PMID: 7379673]
29. Prior A, Maxton DG, Whorwell PJ. Anorectal manometry in irritable bowel syndrome: differences between diarrhoea and constipation predominant subjects. Gut 1990; 31: 458-462 [PMID: 2338274]
30. Simrén M, Abrahamsson H, Björnsson ES. An exaggerated sensory component of the gastrocolonic response in patients with irritable bowel syndrome. Gut 2001; 48: 20-27 [PMID: 11115818]
31. Harraf F, Schmulson M, Saba L, Niazi N, Fass R, Munakata J, Diehl D, Mertz H, Naliboff B, Mayer EA. Subtypes of constipation predominant irritable bowel syndrome based on rectal perception. Gut 1998; 43: 388-394 [PMID: 9863485]
32. Slater BJ, Plusa SM, Smith AN, Varma JS. Rectal hypersensitivity in the irritable bowel syndrome. Int J Colorectal Dis 1997; 12: 29-32 [PMID: 9112147]
33. Steens J, Van Der Schaar PJ, Penning C, Brussee J, Masclee AA. Compliance, tone and sensitivity of the rectum in different subtypes of irritable bowel syndrome. Neurogastroenterol Motil 2002; 14: 241-247 [PMID: 12061908]
34. Chen J, Winston JH, Sarna SK. Neurological and cellular regulation of visceral hypersensitivity induced by chronic stress and colonic inflammation in rats. Neuroscience 2013; 248C: 469-478 [PMID: 23806714 DOI: 10.1016/j.neuroscience.2013.06.024]
35. Christianson JA, Bielefeldt K, Altier C, Cenac N, Davis BM, Gebhart GF, High KW, Kollarik M, Randich A, Undem B, Vergnolle N. Development, plasticity and modulation of visceral afferents. Brain Res Rev 2009; 60 : 171-186 [PMID: 19150371 DOI: 10.1016/j.brainresrev.2008.12.004]
36. Christianson JA, Bielefeldt K, Malin SA, Davis BM. Neonatal colon insult alters growth factor expression and TRPA1 responses in adult mice. Pain 2010; 151 : 540-549 [PMID: 20850221 DOI: 10.1016/j.pain.2010.08.029]
37. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009; 136: 1979-1988 [PMID: 19457422]
38. Vergnolle N. Postinflammatory visceral sensitivity and pain mechanisms. Neurogastroenterol Motil 2008; 20 Suppl 1: 73-80 [PMID: 18402644 DOI: 10.1111/j.1365-2982.2008.01110.x]
39. Moore BA, Stewart TM, Hill C, Vanner SJ. TNBS ileitis evokes hyperexcitability and changes in ionic membrane properties of nociceptive DRG neurons. Am J Physiol Gastrointest Liver Physiol 2002; 282: G1045-G1051 [PMID: 12016130 DOI: 10.1152/ajpgi.00406.2001]
40. Elsenbruch S. Abdominal pain in Irritable Bowel Syndrome: a review of putative psychological, neural and neuro-immune mechanisms. Brain Behav Immun 2011; 25: 386-394 [PMID: 21094682]
41. Blankstein U, Chen J, Diamant NE, Davis KD. Altered brain structure in irritable bowel syndrome: potential contributions of pre-existing and disease-driven factors. Gastroenterology 2010; 138: 1783-1789 [PMID: 20045701 DOI: 10.1053/j.gastro.2009.12.043]
42. Seminowicz DA, Labus JS, Bueller JA, Tillisch K, Naliboff BD, Bushnell MC, Mayer EA. Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology 2010; 139: 48-57.e2 [PMID: 20347816 DOI: 10.1053/j.gastro.2010.03.049]
43. Chen JY, Blankstein U, Diamant NE, Davis KD. White matter abnormalities in irritable bowel syndrome and relation to individual factors. Brain Res 2011; 1392: 121-131 [PMID: 21466788 DOI: 10.1016/j.brainres.2011.03.069]
44. Tillisch K, Mayer EA, Labus JS. Quantitative meta-analysis identifies brain regions activated during rectal distension in irritable bowel syndrome. Gastroenterology 2011; 140: 91-100 [PMID: 20696168 DOI: 10.1053/j.gastro.2010.07.053]
45. Mertz H, Morgan V, Tanner G, Pickens D, Price R, Shyr Y, Kessler R. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000; 118: 842-848 [PMID: 10784583]
46. Hall GB, Kamath MV, Collins S, Ganguli S, Spaziani R, Miranda KL, Bayati A, Bienenstock J. Heightened central affective response to visceral sensations of pain and discomfort in IBS. Neurogastroenterol Motil 2010; 22: 276-e80 [PMID: 20003075 DOI: 10.1111/j.1365-2982.2009.01436.x]
47. Labus JS, Naliboff BN, Fallon J, Berman SM, Suyenobu B, Bueller JA, Mandelkern M, Mayer EA. Sex differences in brain activity during aversive visceral stimulation and its expectation in patients with chronic abdominal pain: a network analysis. Neuroimage 2008; 41: 1032-1043 [PMID: 18450481 DOI: 10.1016/j.neuroimage.2008.03.009]
48. Selye H. A syndrome produced by diverse nocuous agents. 1936. J Neuropsychiatry Clin Neurosci 1998; 10: 230-231 [PMID: 9722327]
49. Folks DG. The interface of psychiatry and irritable bowel syndrome. Curr Psychiatry Rep 2004; 6 : 210-215 [PMID: 15142474]
50. Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998; 43: 256-261 [PMID: 10189854]
51. Gué M, Tekamp A, Tabis N, Junien JL, Buéno L. Cholecystokinin blockade of emotional stress- and CRF-induced colonic motor alterations in rats: role of the amygdala. Brain Res 1994; 658: 232-238 [PMID: 7834346]
52. Tougas G . The autonomic nervous system in functional bowel disorders. Gut 2000; 47 Suppl 4: iv78-i80; discussion iv87 [PMID: 11076926]
53. Dinan TG, Quigley EM, Ahmed SM, Scully P, O'Brien S, O'Mahony L, O'Mahony S, Shanahan F, Keeling PW. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker? Gastroenterology 2006; 130: 304-311 [PMID: 16472586]
54. Chang L, Sundaresh S, Elliott J, Anton PA, Baldi P, Licudine A, Mayer M, Vuong T, Hirano M, Naliboff BD, Ameen VZ, Mayer EA. Dysregulation of the hypothalamic-pituitaryadrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil 2009; 21: 149-159 [PMID: 18684212 DOI: 10.1111/j.1365-2982.2008.01171.x]
55. Kostich WA, Chen A, Sperle K, Largent BL. Molecular identification and analysis of a novel human corticotropin-releasing factor (CRF) receptor: the CRF2gamma receptor. Mol Endocrinol 1998; 12: 1077-1085 [PMID: 9717834]
56. Sánchez MM, Young LJ, Plotsky PM, Insel TR. Autoradiographic and in situ hybridization localization of corticotropin-releasing factor 1 and 2 receptors in nonhuman primate brain. J Comp Neurol 1999; 408: 365-377 [PMID: 10340512]
57. Reyes BA, Valentino RJ, Van Bockstaele EJ. Stress-induced intracellular trafficking of corticotropin-releasing factor receptors in rat locus coeruleus neurons. Endocrinology 2008; 149: 122-130 [PMID: 17947354]
58. Swanson LW, Sawchenko PE, Rivier J, Vale WW. Organization of ovine corticotropin-releasing factor immunoreactive cells and fibers in the rat brain: an immunohistochemical study. Neuroendocrinology 1983; 36: 165-186 [PMID: 6601247]
59. Chatzaki E, Crowe PD, Wang L, Million M, Taché Y, Grigoriadis DE. CRF receptor type 1 and 2 expression and anatomical distribution in the rat colon. J Neurochem 2004; 90: 309-316 [PMID: 15228587]
60. Muramatsu Y, Fukushima K, Iino K, Totsune K, Takahashi K, Suzuki T, Hirasawa G, Takeyama J, Ito M, Nose M, Tashiro A, Hongo M, Oki Y, Nagura H, Sasano H. Urocortin and corticotropin-releasing factor receptor expression in the human colonic mucosa. Peptides 2000; 21: 1799-1809 [PMID: 11150640]
61. Barquist E, Zinner M, Rivier J, Taché Y. Abdominal surgery-induced delayed gastric emptying in rats: role of CRF and sensory neurons. Am J Physiol 1992; 262: G616-G620 [PMID: 1566844]
62. Mönnikes H, Schmidt BG, Taché Y. Psychological stress-induced accelerated colonic transit in rats involves hypothalamic corticotropin-releasing factor. Gastroenterology 1993; 104: 716-723 [PMID: 8440432]
63. Gue M, Junien JL, Bueno L. Conditioned emotional response in rats enhances colonic motility through the central release of corticotropin-releasing factor. Gastroenterology 1991; 100: 964-970 [PMID: 2001832]
64. Sagami Y, Shimada Y, Tayama J, Nomura T, Satake M, Endo Y, Shoji T, Karahashi K, Hongo M, Fukudo S. Effect of a corticotropin releasing hormone receptor antagonist on colonic sensory and motor function in patients with irritable bowel syndrome. Gut 2004; 53: 958-964 [PMID: 15194643]
65. Trimble N, Johnson AC, Foster A, Greenwood-van Meerveld B. Corticotropin-releasing factor receptor 1-deficient mice show decreased anxiety and colonic sensitivity. Neurogastroenterol Motil 2007; 19: 754-760 [PMID: 17539891]
66. Smith GW, Aubry JM, Dellu F, Contarino A, Bilezikjian LM, Gold LH, Chen R, Marchuk Y, Hauser C, Bentley CA, Sawchenko PE, Koob GF, Vale W, Lee KF. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 1998; 20: 1093-1102 [PMID: 9655498]
67. Williams CL, Peterson JM, Villar RG, Burks TF. Corticotropin-releasing factor directly mediates colonic responses to stress. Am J Physiol 1987; 253: G582-G586 [PMID: 2821826]
68. Lu L, Liu D, Ceng X, Ma L. Differential roles of corticotropin-releasing factor receptor subtypes 1 and 2 in opiate withdrawal and in relapse to opiate dependence. Eur J Neurosci 2000; 12: 4398-4404 [PMID: 11122350]
69. Martínez V, Wang L, Rivier J, Grigoriadis D, Taché Y. Central CRF, urocortins and stress increase colonic transit via CRF1 receptors while activation of CRF2 receptors delays gastric transit in mice. J Physiol 2004; 556: 221-234 [PMID: 14755002]
70. Taché Y, Bonaz B. Corticotropin-releasing factor receptors and stress-related alterations of gut motor function. J Clin Invest 2007; 117: 33-40 [PMID: 17200704]
71. Teitelbaum AA, Gareau MG, Jury J, Yang PC, Perdue MH. Chronic peripheral administration of corticotropin-releasing factor causes colonic barrier dysfunction similar to psychological stress. Am J Physiol Gastrointest Liver Physiol 2008; 295: G452-G459 [PMID: 18635602]
72. Martinez V, Taché Y. CRF1 receptors as a therapeutic target for irritable bowel syndrome. Curr Pharm Des 2006; 12: 4071-4088 [PMID: 17100612]
73. Tjong YW, Ip SP, Lao L, Wu J, Fong HH, Sung JJ, Berman B, Che CT. Neonatal maternal separation elevates thalamic corticotrophin releasing factor type 1 receptor expression response to colonic distension in rat. Neuro Endocrinol Lett 2010; 31: 215-220 [PMID: 20424584]
74. Gué M, Del Rio-Lacheze C, Eutamene H, Théodorou V, Fioramonti J, Buéno L. Stress-induced visceral hypersensitivity to rectal distension in rats: role of CRF and mast cells. Neurogastroenterol Motil 1997; 9: 271-279 [PMID: 9430796]
75. Holsboer F, Ising M. Central CRH system in depression and anxiety - evidence from clinical studies with CRH1 receptor antagonists. Eur J Pharmacol 2008; 583: 350-357 [PMID: 18272149 DOI: 10.1016/j.ejphar.2007.12.032]
76. Taché Y, Million M, Nelson AG, Lamy C, Wang L. Role of corticotropin-releasing factor pathways in stress-related alterations of colonic motor function and viscerosensibility in female rodents. Gend Med 2005; 2: 146-154 [PMID: 16290887]
77. Larauche M, Kiank C, Tache Y. Corticotropin releasing factor signaling in colon and ileum: regulation by stress and pathophysiological implications. J Physiol Pharmacol 2009; 60 Suppl 7: 33-46 [PMID: 20388944]
78. Million M, Grigoriadis DE, Sullivan S, Crowe PD, McRoberts JA, Zhou H, Saunders PR, Maillot C, Mayer EA, Taché Y. A novel water-soluble selective CRF1 receptor antagonist, NBI 35965, blunts stress-induced visceral hyperalgesia and colonic motor function in rats. Brain Res 2003; 985 : 32-42 [PMID: 12957366]
79. Taché Y, Martinez V, Million M, Rivier J. Corticotropin-releasing factor and the brain-gut motor response to stress. Can J Gastroenterol 1999; 13 Suppl A: 18A-25A [PMID: 10202204]
80. Söderholm JD, Perdue MH. Stress and gastrointestinal tract. II. Stress and intestinal barrier function. Am J Physiol Gastrointest Liver Physiol 2001; 280: G7-G13 [PMID: 11123192]
81. Nakade Y, Fukuda H, Iwa M, Tsukamoto K, Yanagi H, Yamamura T, Mantyh C, Pappas TN, Takahashi T. Restraint stress stimulates colonic motility via central corticotropin-releasing factor and peripheral 5-HT3 receptors in conscious rats. Am J Physiol Gastrointest Liver Physiol 2007; 292 : G1037-G1044 [PMID: 17158256 DOI: 10.1152/ajpgi.00419.2006]
82. Konturek SJ, Brzozowski T, Konturek PC, Zwirska-Korczala K, Reiter RJ. Day/night differences in stress-induced gastric lesions in rats with an intact pineal gland or after pinealectomy. J Pineal Res 2008; 44: 408-415 [PMID: 18086146 DOI: 10.1111/j.1600-079X.2007.00543.x]
83. Castagliuolo I, Lamont JT, Qiu B, Fleming SM, Bhaskar KR, Nikulasson ST, Kornetsky C, Pothoulakis C. Acute stress causes mucin release from rat colon: role of corticotropin releasing factor and mast cells. Am J Physiol 1996; 271 : G884-G892 [PMID: 8944704]
84. Castagliuolo I, Wershil BK, Karalis K, Pasha A, Nikulasson ST, Pothoulakis C. Colonic mucin release in response to immobilization stress is mast cell dependent. Am J Physiol 1998; 274: G1094-G1100 [PMID: 9696710]
85. Griebel G, Holsboer F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat Rev Drug Discov 2012; 11: 462-478 [PMID: 22596253 DOI: 10.1038/nrd3702]
86. de Kloet ER, Joëls M, Holsboer F. Stress and the brain: from adaptation to disease. Nat Rev Neurosci 2005; 6 : 463-475 [PMID: 15891777 DOI: 10.1038/nrn1683]
87. Gunter WD, Shepard JD, Foreman RD, Myers DA, Greenwood-Van Meerveld B. Evidence for visceral hypersensitivity in high-anxiety rats. Physiol Behav 2000; 69: 379-382 [PMID: 10869605]
88. Myers B, Dittmeyer K, Greenwood-Van Meerveld B. Involvement of amygdaloid corticosterone in altered visceral and somatic sensation. Behav Brain Res 2007; 181 : 163-167 [PMID: 17481745 DOI: 10.1016/j.bbr.2007.03.031]
89. Venkova K, Foreman RD, Greenwood-Van Meerveld B. Mineralocorticoid and glucocorticoid receptors in the amygdala regulate distinct responses to colorectal distension. Neuropharmacology 2009; 56: 514-521 [PMID: 18977372 DOI: 10.1016/j.neuropharm.2008.10.004]
90. Myers B, Greenwood-Van Meerveld B. Elevated corticosterone in the amygdala leads to persistent increases in anxiety-like behavior and pain sensitivity. Behav Brain Res 2010; 214: 465-469 [PMID: 20573588 DOI: 10.1016/j.bbr.2010.05.049]
91. Simrén M, Abrahamsson H, Björnsson ES. Lipid-induced colonic hypersensitivity in the irritable bowel syndrome: the role of bowel habit, sex, and psychologic factors. Clin Gastroenterol Hepatol 2007; 5: 201-208 [PMID: 17174611]
92. Ragnarsson G, Bodemar G. Pain is temporally related to eating but not to defaecation in the irritable bowel syndrome (IBS). Patients' description of diarrhea, constipation and symptom variation during a prospective 6-week study. Eur J Gastroenterol Hepatol 1998; 10: 415-421 [PMID: 9619389]
93. Simrén M, Ma˚nsson A, Langkilde AM, Svedlund J, Abrahamsson H, Bengtsson U, Björnsson ES. Food-related gastrointestinal symptoms in the irritable bowel syndrome. Digestion 2001; 63: 108-115 [PMID: 11244249]
94. Rogers J, Henry MM, Misiewicz JJ. Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome. Gut 1989; 30 : 634-641 [PMID: 2731756]
95. Evans PR, Kellow JE. Physiological modulation of jejunal sensitivity in health and in irritable bowel syndrome. Am J Gastroenterol 1998; 93 : 2191-2196 [PMID: 9820395 DOI: 10.1111/j.1572-0241.1998.00534.x]
96. Barrett JS, Gibson PR. Fermentable oligosaccharides, disaccharides, monosaccharides and polyols (FODMAPs) and nonallergic food intolerance: FODMAPs or food chemicals? Therap Adv Gastroenterol 2012; 5: 261-268 [PMID: 22778791 DOI: 10.1177/1756283X11436241]
97. Gearry RB, Irving PM, Barrett JS, Nathan DM, Shepherd SJ, Gibson PR. Reduction of dietary poorly absorbed shortchain carbohydrates (FODMAPs) improves abdominal symptoms in patients with inflammatory bowel disease-a pilot study. J Crohns Colitis 2009; 3 : 8-14 [PMID: 21172242 DOI: 10.1016/j.crohns.2008.09.004]
98. Staudacher HM, Whelan K, Irving PM, Lomer MC. Comparison of symptom response following advice for a diet low in fermentable carbohydrates (FODMAPs) versus standard dietary advice in patients with irritable bowel syndrome. J Hum Nutr Diet 2011; 24: 487-495 [PMID: 21615553 DOI: 10.1111/j.1365-277X.2011.01162.x]
99. Barrett JS, Gearry RB, Muir JG, Irving PM, Rose R, Rosella O, Haines ML, Shepherd SJ, Gibson PR. Dietary poorly absorbed, short-chain carbohydrates increase delivery of water and fermentable substrates to the proximal colon. Aliment Pharmacol Ther 2010; 31: 874-882 [PMID: 20102355 DOI: 10.1111/j.1365-2036.2010.04237.x]
100. Hellström PM, Näslund E, Edholm T, Schmidt PT, Kristensen J, Theodorsson E, Holst JJ, Efendic S. GLP-1 suppresses gastrointestinal motility and inhibits the migrating motor complex in healthy subjects and patients with irritable bowel syndrome. Neurogastroenterol Motil 2008; 20 : 649-659 [PMID: 18298441]
101. McKee DP, Quigley EM. Intestinal motility in irritable bowel syndrome: is IBS a motility disorder? Part 1. Definition of IBS and colonic motility. Dig Dis Sci 1993; 38: 1761-1772 [PMID: 8404395]
102. Quigley EM. Antibiotics for irritable bowel syndrome: hitting the target, but what is it? Gastroenterology 2011; 141 : 391-393 [PMID: 21620844]
103. Nakade Y, Tsukamoto K, Iwa M, Pappas TN, Takahashi T. Glucagon like peptide-1 accelerates colonic transit via central CRF and peripheral vagal pathways in conscious rats. Auton Neurosci 2007; 131: 50-56 [PMID: 16938493]
104. Lim GE, Huang GJ, Flora N, LeRoith D, Rhodes CJ, Brubaker PL. Insulin regulates glucagon-like peptide-1 secretion from the enteroendocrine L cell. Endocrinology 2009; 150 : 580-591 [PMID: 18818290 DOI: 10.1210/en.2008-0726]
105. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997; 138: 4445-4455 [PMID: 9322962]
106. Simrén M, Björnsson ES, Abrahamsson H. High interdigestive and postprandial motilin levels in patients with the irritable bowel syndrome. Neurogastroenterol Motil 2005; 17: 51-57 [PMID: 15670264 DOI: 10.1111/j.1365-2982.2004.00582.x]
107. Zhang H, Yan Y, Shi R, Lin Z, Wang M, Lin L. Correlation of gut hormones with irritable bowel syndrome. Digestion 2008; 78: 72-76 [PMID: 18948690 DOI: 10.1159/000165352]
108. Simrén M, Stotzer PO, Sjövall H, Abrahamsson H, Björnsson ES. Abnormal levels of neuropeptide Y and peptide YY in the colon in irritable bowel syndrome. Eur J Gastroenterol Hepatol 2003; 15: 55-62 [PMID: 12544695]
109. Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, Ardid D. Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome. Aliment Pharmacol Ther 2012; 36: 1009-1031 [PMID: 23066886 DOI: 10.1111/apt.12080]
110. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14: 32-39 [PMID: 17924558 DOI: 10.1002/ibd.20275]
111. Sidhu R, Drew K, McAlindon ME, Lobo AJ, Sanders DS. Elevated serum chromogranin A in irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD): a shared model for pathogenesis? Inflamm Bowel Dis 2010; 16: 361 [PMID: 19575362 DOI: 10.1002/ibd.20982]
112. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006; 131: 445-450; quiz 660 [PMID: 16890598]
113. Halvorson HA, Schlett CD, Riddle MS. Postinfectious irritable bowel syndrome - a meta-analysis. Am J Gastroenterol 2006; 101: 1894-1899; quiz 1942 [PMID: 16928253]
114. Gwee KA, Leong YL, Graham C, McKendrick MW, Collins SM, Walters SJ, Underwood JE, Read NW. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44: 400-406 [PMID: 10026328]
115. Kai Y, Takahashi I, Ishikawa H, Hiroi T, Mizushima T, Matsuda C, Kishi D, Hamada H, Tamagawa H, Ito T, Yoshizaki K, Kishimoto T, Matsuda H, Kiyono H. Colitis in mice lacking the common cytokine receptor gamma chain is mediated by IL-6-producing CD4+ T cells. Gastroenterology 2005; 128: 922-934 [PMID: 15825075]
116. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53: 1096-1101 [PMID: 15247174 DOI: 10.1136/gut.2003.021154]
117. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314 : 779-782 [PMID: 9080994]
118. Chadwick VS, Chen W, Shu D, Paulus B, Bethwaite P, Tie A, Wilson I. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002; 122: 1778-1783 [PMID: 12055584]
119. Goral V, Kucukoner M, Buyukbayram H. Mast cells count and serum cytokine levels in patients with irritable bowel syndrome. Hepatogastroenterology 2010; 57 : 751-754 [PMID: 21033222]
120. Chang L, Adeyemo M, Karagiannides I, Videlock EJ, Bowe C, Shih W, Presson AP, Yuan PQ, Cortina G, Gong H, Singh S, Licudine A, Mayer M, Tache Y, Pothoulakis C, Mayer EA. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012; 107: 262-272 [PMID: 22158028 DOI: 10.1038/ajg.2011.423]
121. Barbara G, Wang B, Stanghellini V, de Giorgio R, Cremon C, Di Nardo G, Trevisani M, Campi B, Geppetti P, Tonini M, Bunnett NW, Grundy D, Corinaldesi R. Mast cell-dependent excitation of visceral-nociceptive sensory neurons in irritable bowel syndrome. Gastroenterology 2007; 132: 26-37 [PMID: 17241857]
122. Collins SM. The immunomodulation of enteric neuromuscular function: implications for motility and inflammatory disorders. Gastroenterology 1996; 111 : 1683-1699 [PMID: 8942751]
123. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011; 33: 1045-1052 [PMID: 21453321 DOI: 10.1111/j.1365-2036.2011.04624.x]
124. Dinan TG, Clarke G, Quigley EM, Scott LV, Shanahan F, Cryan J, Cooney J, Keeling PW. Enhanced cholinergic-mediated increase in the pro-inflammatory cytokine IL-6 in irritable bowel syndrome: role of muscarinic receptors. Am J Gastroenterol 2008; 103: 2570-2576 [PMID: 18785949]
125. Liebregts T, Adam B, Bredack C, Röth A, Heinzel S, Lester S, Downie-Doyle S, Smith E, Drew P, Talley NJ, Holtmann G. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007; 132: 913-920 [PMID: 17383420]
126. Kindt S, Van Oudenhove L, Broekaert D, Kasran A, Ceuppens JL, Bossuyt X, Fischler B, Tack J. Immune dysfunction in patients with functional gastrointestinal disorders. Neurogastroenterol Motil 2009; 21: 389-398 [PMID: 19126184 DOI: 10.1111/j.1365-2982.2008.01220.x]
127. Elsenbruch S, Holtmann G, Oezcan D, Lysson A, Janssen O, Goebel MU, Schedlowski M. Are there alterations of neuroendocrine and cellular immune responses to nutrients in women with irritable bowel syndrome? Am J Gastroenterol 2004; 99 : 703-710 [PMID: 15089905 DOI: 10.1111/j.1572-0241.2004.04138.x]
128. Coëffier M, Gloro R, Boukhettala N, Aziz M, Lecleire S, Vandaele N, Antonietti M, Savoye G, Bôle-Feysot C, Déchelotte P, Reimund JM, Ducrotté P. Increased proteasome-mediated degradation of occludin in irritable bowel syndrome. Am J Gastroenterol 2010; 105: 1181-1188 [PMID: 19997094]
129. Macsharry J, O'Mahony L, Fanning A, Bairead E, Sherlock G, Tiesman J, Fulmer A, Kiely B, Dinan TG, Shanahan F, Quigley EM. Mucosal cytokine imbalance in irritable bowel syndrome. Scand J Gastroenterol 2008; 43: 1467-1476 [PMID: 18752146]
130. Barbara G, Stanghellini V, De Giorgio R, Cremon C, Cottrell GS, Santini D, Pasquinelli G, Morselli-Labate AM, Grady EF, Bunnett NW, Collins SM, Corinaldesi R. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004; 126: 693-702 [PMID: 14988823]
131. Buhner S, Li Q, Vignali S, Barbara G, De Giorgio R, Stanghellini V, Cremon C, Zeller F, Langer R, Daniel H, Michel K, Schemann M. Activation of human enteric neurons by supernatants of colonic biopsy specimens from patients with irritable bowel syndrome. Gastroenterology 2009; 137 : 1425-1434 [PMID: 19596012]
132. Galli SJ, Nakae S, Tsai M. Mast cells in the development of adaptive immune responses. Nat Immunol 2005; 6: 135-142 [PMID: 15662442]
133. O'Malley D, Liston M, Hyland NP, Dinan TG, Cryan JF. Colonic soluble mediators from the maternal separation model of irritable bowel syndrome activate submucosal neurons via an interleukin-6-dependent mechanism. Am J Physiol Gastrointest Liver Physiol 2011; 300: G241-G252 [PMID: 21109592]
134. Xia Y, Hu HZ, Liu S, Ren J, Zafirov DH, Wood JD. IL-1beta and IL-6 excite neurons and suppress nicotinic and noradrenergic neurotransmission in guinea pig enteric nervous system. J Clin Invest 1999; 103: 1309-1316 [PMID: 10225974]
135. Rehn M, Hübschle T, Diener M. TNF-alpha hyperpolarizes membrane potential and potentiates the response to nicotinic receptor stimulation in cultured rat myenteric neurones. Acta Physiol Scand 2004; 181: 13-22 [PMID: 15086448]
136. Zhang L, Hu L, Chen M, Yu B. Exogenous interleukin-6 facilitated the contraction of the colon in a depression rat model. Dig Dis Sci 2013; 58 : 2187-2196 [PMID: 23589140 DOI: 10.1007/s10620-013-2656-3]
137. Natale L, Piepoli AL, De Salvia MA, De Salvatore G, Mitolo CI, Marzullo A, Portincasa P, Moschetta A, Palasciano G, Mitolo-Chieppa D. Interleukins 1 beta and 6 induce functional alteration of rat colonic motility: an in vitro study. Eur J Clin Invest 2003; 33: 704-712 [PMID: 12864781]
138. Kindt S, Vanden Berghe P, Boesmans W, Roosen L, Tack J. Prolonged IL-1beta exposure alters neurotransmitter and electrically induced Ca(2+) responses in the myenteric plexus. Neurogastroenterol Motil 2010; 22 : 321-e85 [PMID: 19796332]
139. Rühl A, Hurst S, Collins SM. Synergism between interleukins 1 beta and 6 on noradrenergic nerves in rat myenteric plexus. Gastroenterology 1994; 107: 993-1001 [PMID: 7926489]
140. De Jongh RF, Vissers KC, Meert TF, Booij LH, De Deyne CS, Heylen RJ. The role of interleukin-6 in nociception and pain. Anesth Analg 2003; 96: 1096-1103, table of contents [PMID: 12651667]
141. Dunlop SP, Hebden J, Campbell E, Naesdal J, Olbe L, Perkins AC, Spiller RC. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006; 101: 1288-1294 [PMID: 16771951]
142. Piche T, Barbara G, Aubert P, Bruley des Varannes S, Dainese R, Nano JL, Cremon C, Stanghellini V, De Giorgio R, Galmiche JP, Neunlist M. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009; 58 : 196-201 [PMID: 18824556]
143. Hiribarren A, Heyman M, L'Helgouac'h A, Desjeux JF. Effect of cytokines on the epithelial function of the human colon carcinoma cell line HT29 cl 19A. Gut 1993; 34: 616-620 [PMID: 8504961]
144. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009; 146: 41-46 [PMID: 19595511]
145. Cremonini F, Talley NJ. Treatments targeting putative mechanisms in irritable bowel syndrome. Nat Clin Pract Gastroenterol Hepatol 2005; 2: 82-88 [PMID: 16265125]
146. Bravo JA, Forsythe P, Chew MV, Escaravage E, Savignac HM, Dinan TG, Bienenstock J, Cryan JF. Ingestion of Lactobacillus strain regulates emotional behavior and central GABA receptor expression in a mouse via the vagus nerve. Proc Natl Acad Sci USA 2011; 108 : 16050-16055 [PMID: 21876150 DOI: 10.1073/pnas.1102999108]
147. Mättö J, Maunuksela L, Kajander K, Palva A, Korpela R, Kassinen A, Saarela M. Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome-a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 2005; 43: 213-222 [PMID: 15747442]
148. Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005; 100: 373-382 [PMID: 15667495 DOI: 10.1111/j.1572-0241.2005.40312.x]
149. Kassinen A, Krogius-Kurikka L, Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 2007; 133: 24-33 [PMID: 17631127]
150. Jeffery IB, O'Toole PW, Öhman L, Claesson MJ, Deane J, Quigley EM, Simrén M. An irritable bowel syndrome subtype defined by species-specific alterations in faecal microbiota. Gut 2012; 61: 997-1006 [PMID: 22180058 DOI: 10.1136/gutjnl-2011-301501]
151. Yoon JS, Sohn W, Lee OY, Lee SP, Lee KN, Jun DW, Lee HL, Yoon BC, Choi HS, Chung WS, Seo JG. Effect of multispecies probiotics on irritable bowel syndrome: a randomized, double-blind, placebo-controlled trial. J Gastroenterol Hepatol 2014; 29: 52-59 [PMID: 23829297 DOI: 10.1111/jgh.12322]
152. O'Mahony L, McCarthy J, Kelly P, Hurley G, Luo F, Chen K, O'Sullivan GC, Kiely B, Collins JK, Shanahan F, Quigley EM. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005; 128 : 541-551 [PMID: 15765388]
153. Prakash S, Rodes L, Coussa-Charley M, Tomaro-Duchesneau C. Gut microbiota: next frontier in understanding human health and development of biotherapeutics. Biologics 2011; 5: 71-86 [PMID: 21847343 DOI: 10.2147/BTT.S19099]
154. O'Mahony C, Scully P, O'Mahony D, Murphy S, O'Brien F, Lyons A, Sherlock G, MacSharry J, Kiely B, Shanahan F, O' Mahony L. Commensal-induced regulatory T cells mediate protection against pathogen-stimulated NF-kappaB activation. PLoS Pathog 2008; 4: e1000112 [PMID: 18670628 DOI: 10.1371/journal.ppat.1000112]
155. Lee BJ, Bak YT. Irritable bowel syndrome, gut microbiota and probiotics. J Neurogastroenterol Motil 2011; 17 : 252-266 [PMID: 21860817 DOI: 10.5056/jnm.2011.17.3.252]
156. Begtrup LM, de Muckadell OB, Kjeldsen J, Christensen RD, Jarbøl DE. Long-term treatment with probiotics in primary care patients with irritable bowel syndrome - a randomised, double-blind, placebo controlled trial. Scand J Gastroenterol 2013; 48: 1127-1135 [PMID: 23957590 DOI: 10.3109/00365521.2013.825314]
157. Roberts LM, McCahon D, Holder R, Wilson S, Hobbs FD. A randomised controlled trial of a probiotic 'functional food' in the management of irritable bowel syndrome. BMC Gastroenterol 2013; 13: 45 [PMID: 23496803 DOI: 10.1186/1471-230X-13-45]
158. Bloom JR, Stewart SL, Chang S, Banks PJ. Then and now: quality of life of young breast cancer survivors. Psychooncology 2004; 13 : 147-160 [PMID: 15022150 DOI: 10.1002/pon.794]
159. Mayer EA. The neurobiology of stress and gastrointestinal disease. Gut 2000; 47: 861-869 [PMID: 11076888]
160. Barbara G, Stanghellini V, Cremon C, De Giorgio R, Gargano L, Cogliandro R, Pallotti F, Corinaldesi R. Probiotics and irritable bowel syndrome: rationale and clinical evidence for their use. J Clin Gastroenterol 2008; 42 Suppl 3 Pt 2: S214-S217 [PMID: 18685517]
161. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003; 125: 1651-1659 [PMID: 14724817]
162. Gwee KA, Graham JC, McKendrick MW, Collins SM, Marshall JS, Walters SJ, Read NW. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347: 150-153 [PMID: 8544549]
163. Pawlak CR, Jacobs R, Mikeska E, Ochsmann S, Lombardi MS, Kavelaars A, Heijnen CJ, Schmidt RE, Schedlowski M. Patients with systemic lupus erythematosus differ from healthy controls in their immunological response to acute psychological stress. Brain Behav Immun 1999; 13: 287-302 [PMID: 10600217]
164. Ackerman KD, Martino M, Heyman R, Moyna NM, Rabin BS. Immunologic response to acute psychological stress in MS patients and controls. J Neuroimmunol 1996; 68 : 85-94 [PMID: 8784264]
165. Leonard BE. Changes in the immune system in depression and dementia: causal or co-incidental effects? Int J Dev Neurosci 2001; 19: 305-312 [PMID: 11337199]
166. Zheng PY, Feng BS, Oluwole C, Struiksma S, Chen X, Li P, Tang SG, Yang PC. Psychological stress induces eosinophils to produce corticotrophin releasing hormone in the intestine. Gut 2009; 58: 1473-1479 [PMID: 19651632 DOI: 10.1136/gut.2009.181701]
167. Söderholm JD, Yang PC, Ceponis P, Vohra A, Riddell R, Sherman PM, Perdue MH. Chronic stress induces mast cell-dependent bacterial adherence and initiates mucosal inflammation in rat intestine. Gastroenterology 2002; 123: 1099-1108 [PMID: 12360472]
168. Song C, Earley B, Leonard BE. Behavioral, neurochemical, and immunological responses to CRF administration. Is CRF a mediator of stress? Ann N Y Acad Sci 1995; 771: 55-72 [PMID: 8597429]
169. O'Malley D, Cryan JF, Dinan TG. Crosstalk between interleukin-6 and corticotropin-releasing factor modulate submucosal plexus activity and colonic secretion. Brain Behav Immun 2013; 30 : 115-124 [PMID: 23369733 DOI: 10.1016/j.bbi.2013.01.078]
170. Fekete EM, Zorrilla EP. Physiology, pharmacology, and therapeutic relevance of urocortins in mammals: ancient CRF paralogs. Front Neuroendocrinol 2007; 28: 1-27 [PMID: 17083971]
171. Wu Y, Hu J, Zhang R, Zhou C, Xu Y, Guan X, Li S. Enhanced intracellular calcium induced by urocortin is involved in degranulation of rat lung mast cells. Cell Physiol Biochem 2008; 21: 173-182 [PMID: 18209484]
172. Ando T, Rivier J, Yanaihara H, Arimura A. Peripheral corticotropin-releasing factor mediates the elevation of plasma IL-6 by immobilization stress in rats. Am J Physiol 1998; 275: R1461-R1467 [PMID: 9791062]
173. Saruta M, Takahashi K, Suzuki T, Torii A, Kawakami M, Sasano H. Urocortin 1 in colonic mucosa in patients with ulcerative colitis. J Clin Endocrinol Metab 2004; 89: 5352-5361 [PMID: 15531481]
174. Tsatsanis C, Androulidaki A, Dermitzaki E, Charalampopoulos I, Spiess J, Gravanis A, Margioris AN. Urocortin 1 and Urocortin 2 induce macrophage apoptosis via CRFR2. FEBS Lett 2005; 579: 4259-4264 [PMID: 16054139]
175. Tsatsanis C, Androulidaki A, Dermitzaki E, Gravanis A, Margioris AN. Corticotropin releasing factor receptor 1 (CRF1) and CRF2 agonists exert an anti-inflammatory effect during the early phase of inflammation suppressing LPS-induced TNF-alpha release from macrophages via induction of COX-2 and PGE2. J Cell Physiol 2007; 210: 774-783 [PMID: 17117478]
176. O'Malley D, Dinan TG, Cryan JF. Altered expression and secretion of colonic interleukin-6 in a stress-sensitive animal model of brain-gut axis dysfunction. J Neuroimmunol 2011; 235: 48-55 [PMID: 21565410 DOI: 10.1016/j.jneuroim.2011.04.003]